Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm

Bibliographic Details
Main Authors:	Steffen Koschmieder, Nicolas Chatain
Format:	Article
Language:	English
Published:	Wiley 2018-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000106

Similar Items

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
by: Julian Baumeister, et al.
Published: (2021-12-01)

The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
by: Steffen Koschmieder
Published: (2021-06-01)

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
by: Kristin Holl, et al.
Published: (2023-08-01)

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
by: Kristin Holl, et al.
Published: (2024-02-01)

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.
by: Martin M J Kirschner, et al.
Published: (2015-01-01)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
by: Sylvie Hermouet, et al.
Published: (2023-05-01)

Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.
by: Richard K Lubberich, et al.
Published: (2018-01-01)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
by: Holly L. Geyer, et al.
Published: (2015-01-01)

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
by: Sylvie Hermouet, et al.
Published: (2015-01-01)

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
by: Margherita Vieri, et al.
Published: (2023-11-01)

Myeloproliferative neoplasms
by: Jean-Jacques Kiladjian
Published: (2018-06-01)

Myeloproliferative neoplasms
by: Nick Cross, (Coordinating Author)
Published: (2019-06-01)

Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms
by: Luca Malcovati, et al.
Published: (2014-11-01)

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
by: Sylvie Hermouet, et al.
Published: (2015-01-01)

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm
by: Angela G. Fleischman
Published: (2015-01-01)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
by: Kathrin Olschok, et al.
Published: (2023-10-01)

The microenvironment in myeloproliferative neoplasm
by: Simón Méndez-Ferrer, et al.
Published: (2018-06-01)

Spleen in myeloproliferative neoplasms
by: Giovanni Barosi
Published: (2018-06-01)

Epigenetics in myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2023-07-01)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
by: Stefan N. Constantinescu, et al.
Published: (2021-06-01)

HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms
by: Margaux Sevin, et al.
Published: (2015-01-01)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
by: Kathrin Olschok, et al.
Published: (2023-08-01)

CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
by: Paola Guglielmelli, et al.
Published: (2010-05-01)

CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
by: Lisa Pieri, et al.
Published: (2010-06-01)

“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms
by: Hélène F.E. Gleitz, et al.
Published: (2022-08-01)

The Hematopoietic Niche in Myeloproliferative Neoplasms
by: Annette H. Schmitt-Graeff, et al.
Published: (2015-01-01)

Pathophysiology of thrombosis in myeloproliferative neoplasms
by: Raffaele Landolfi, et al.
Published: (2011-02-01)

Autoimmunity and the risk of myeloproliferative neoplasms
by: Sigurdur Y. Kristinsson, et al.
Published: (2010-07-01)

Interferons in the treatment of myeloproliferative neoplasms
by: Pankit Vachhani, et al.
Published: (2024-02-01)

Mutant Calreticulin in the Myeloproliferative Neoplasms
by: Daniel Prins, et al.
Published: (2020-02-01)

Neurological Findings in Myeloproliferative Neoplasms
by: Semra Paydas
Published: (2013-04-01)

Novel therapeutics in myeloproliferative neoplasms
by: Sangeetha Venugopal, et al.
Published: (2020-12-01)

Targeted therapies for myeloproliferative neoplasms
by: Bing Li, et al.
Published: (2019-07-01)

Molecular pathogenesis of the myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2021-06-01)

CALR Mutations in Myeloproliferative Neoplasms
by: Ken-Hong Lim
Published: (2014-06-01)

Myeloproliferative neoplasm stem cells
by: Mead, A, et al.
Published: (2017)

Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms
by: Jessica E. Pritchard, et al.
Published: (2024-01-01)

Myeloproliferative neoplasms – blurring the lines between cancer and chronic inflammatory disorder
by: Eli M. Soyfer, et al.
Published: (2023-06-01)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
by: Eylem Eliaçık, et al.
Published: (2015-05-01)

The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
by: Richard A. Van Etten, et al.
Published: (2011-04-01)